The influence of tegafur combined with capecitabine on inflammatory factors and lymphocyte function of patients with gallbladder cancer
-
摘要: 目的 淋巴细胞及炎症因子在胆囊癌患者中表达异常,本研究通过研究替吉奥联合卡培他滨对胆囊癌患者炎性因子和淋巴细胞功能的影响,探讨其临床治疗机制。 方法 将丽水市中心医院2014年2月-2015年10月收治的84例胆囊癌患者按照随机数字表法分为试验组(42例)和对照组(42例),对照组采用卡培他滨口服治疗,1.5 g/m2,2次/d,试验组加用替吉奥口服治疗,50 mg/m2,2次/d,8周后观察2组患者的临床疗效、临床受益情况和毒副反应。采用ELISA法检测血清TNF-α、IL-6、IL-8炎性因子水平,流式细胞仪测定T细胞亚群CD4+、CD8+细胞,分析其变化情况。 结果 试验组的总有效率为52.38%(22/42),对照组总有效率为33.33%(14/42),秩和检验差异无统计学意义(P>0.05)。试验组的肿瘤控制率为78.57%(33/42),显著高于对照组的57.14%(24/42),差异有统计学意义(P<0.05)。试验组患者的TNF-α、IL-6、IL-8水平低于对照组,差异有统计学意义(P<0.05)。试验组患者的T细胞CD4+、CD8+高于对照组,差异有统计学意义(P<0.05)。2组患者主要不良反应为皮疹、恶心呕吐、肝功能损害,差异无统计学意义(P>0.05)。 结论 替吉奥联合卡培他滨治疗胆囊癌患者疗效较好,降低炎症反应,增强机体免疫功能,不良反应较轻,值得临床推广应用。Abstract: Objective Lymphoid cells and inflammatory factors in patients with gallbladder were abnormal expression,this research study the influence of tegafur combined capecitabine on inflammatory factors and lymphocyte function of patients with gallbladder cancer,to explore its clinical mechanism. Methods Eighty-four cases of patients with gallbladder cancer were divided into experimental group (n=42) and control group (n=42) according to random number table method.The control group treated with oral capecitabine,1.5 g/m2,2 times/day.The experimental group was given tegafur 50 mg/m2,2 times/day combined with oral capecitabine,1.5 g/m2,2 times/day.After 8 weeks,the clinical efficacy,clinical benefit,toxic and side reaction of two groups of patients would be observed.Serum TNF alpha,IL-6,IL-8 levels of inflammatory factors were detected by ELISA.T cell subgroup CD4+,CD8+ cells were detected by Flow cytometry.The clinical effect,inflammatory factors and cellular function were analyzed. Results The total effective rate 52.38%(22/42) of experimental group,and the control group was 33.33%(14/42),the differences were no statistically significant of rank sum test (P>0.05).The tumor control rate 78.57%(33/42) of experimental group was higher than the control group 57.14%(24/42),and the differences were statistically significant (P<0.05).Eight weeks after treatment,the levels of TNF alpha),IL-6 and IL-8 in the experimental group were lower than the control group,the differences were statistically significant (P<0.05).The T cell subgroup CD4+,CD8+ cells in the experimental group were higher than the control group,the differences were statistically significant (P<0.05).Two groups of patients main adverse reactions were rash,nausea,vomiting,liver function damage.There was no statistically significant difference between the two groups (P>0.05). Conclusion Treatment methods of tegafur combined capecitabine for Patients with gallbladder had good recent curative effect,can reduce inflammatory reaction,enhance the body's immune function,had a lighter side reaction.It was Worthy of clinical popularization and application.
-
Key words:
- Gallbladder Cancer /
- Tegafur /
- Capecitabine /
- Inflammatory Factors /
- Lymphocyte Function
点击查看大图
计量
- 文章访问数: 77
- HTML全文浏览量: 15
- PDF下载量: 0
- 被引次数: 0